Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

SPRC

SciSparc Ltd

Dec 11 • 04:00PM ET

0.2547

Dollar change -0.0195
Percentage change -7.11	%

Healthcare • Biotechnology • Israel • NASD

Peers: AXSM ATAI CMPS RLMD INMB MNMD BTAI IMVT CYBN SHPH

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-4.87	Insider Own	0.00%	Shs Outstand	10.36M	Perf Week	10.93%
Market Cap	2.64M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	10.36M	Perf Month	9.45%
Income	-5.68M	PEG	-	EPS next Q	-	Inst Own	1.73%	Short Float	0.93%	Perf Quarter	-11.65%
Sales	1.75M	P/S	1.51	EPS this Y	-	Inst Trans	-3.69%	Short Ratio	0.10	Perf Half Y	-71.39%
Book/sh	1.93	P/B	0.13	EPS next Y	-	ROA	-55.80%	Short Interest	0.10M	Perf Year	-95.40%
Cash/sh	0.25	P/C	1.01	EPS next 5Y	-	ROE	-103.20%	52W Range	0.21 - 7.22	Perf YTD	-94.78%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-55.28%	ROI	-81.83%	52W High	-96.47%	Beta	0.97
Dividend TTM	-	Quick Ratio	1.63	Sales past 5Y	22.75%	Gross Margin	-	52W Low	23.94%	ATR (14)	0.02
Dividend Ex-Date	-	Current Ratio	1.86	EPS Y/Y TTM	-350.84%	Oper. Margin	-395.94%	RSI (14)	54.86	Volatility	10.37% 9.37%
Employees	4	Debt/Eq	0.01	Sales Y/Y TTM	-47.36%	Profit Margin	-325.36%	Recom	1.00	Target Price	520.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-	Payout	-	Rel Volume	0.55	Prev Close	0.27
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	994.43K	Price	0.25
SMA20	7.61%	SMA50	9.04%	SMA200	-71.50%	Trades		Volume	545,731	Change	-7.11%

Nov-30-24 06:10AM	Jeffs Brands announces trademark registration approval for Wellution (TipRanks)
Oct-01-24 06:33AM	SciSparc receives FDA approval for trial for Tourette syndrome therapy (Clinical Trials Arena)
Sep-30-24 09:25AM	SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment (GlobeNewswire)
Sep-26-24 09:05AM	SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX (GlobeNewswire)
Sep-23-24 08:17AM	SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment (GlobeNewswire)
04:09PM	Loading…
Sep-18-24 04:09PM	SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment (GlobeNewswire)
Sep-16-24 04:06PM	SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy (GlobeNewswire) -7.67%
04:06PM	Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy (GlobeNewswire)
Sep-11-24 07:40AM	SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax's Direct Import Agreement with Major Chinese Vehicle Manufacturer (GlobeNewswire)
Sep-06-24 07:55AM	SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment (GlobeNewswire)
07:55AM	Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment (GlobeNewswire)
Aug-29-24 04:25PM	SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination (GlobeNewswire) -13.04%
04:25PM	Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment (GlobeNewswire)
Aug-28-24 08:55AM	SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million (GlobeNewswire)
Aug-26-24 04:52AM	SciSparc secures final approval in Israel to start Tourettes Syndrome trial (Clinical Trials Arena) +7.63%
04:32AM	Loading…
04:32AM	SciSparc seeks FDA IND clearance for Phase IIb Tourette Syndrome treatment trial (Clinical Trials Arena)
Aug-23-24 04:09PM	SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome (GlobeNewswire)
Aug-22-24 08:12AM	SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board (GlobeNewswire) -7.71%
Aug-19-24 04:11PM	SciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 Treatment (GlobeNewswire) +13.51%
06:33AM	SciSparc and Polyrizon sign global agreement for pain therapy (Pharmaceutical Technology)
Aug-16-24 04:30PM	SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 million (GlobeNewswire) -7.27%
Aug-14-24 04:53PM	SciSparc Updates Regarding the Status of the AutoMax Merger (GlobeNewswire) -7.79% +23.87%
Aug-06-24 08:57AM	SciSparc's Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug (GlobeNewswire) +8.47%
Jul-22-24 08:20AM	SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung Cancer (GlobeNewswire)
Jul-17-24 07:07AM	SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million (GlobeNewswire) -11.33%
Jul-16-24 11:55AM	SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification (GlobeNewswire)
11:01AM	Mizuho Just Issued a Warning on Palantir (PLTR) Stock (InvestorPlace)
10:43AM	Why Is SciSparc (SPRC) Stock Up 25% Today? (InvestorPlace)
07:43AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
06:03AM	SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss (GlobeNewswire)
06:03AM	Loading…
06:03AM	Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss (GlobeNewswire)
Jul-08-24 08:30AM	SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded Company (GlobeNewswire)
May-31-24 07:17AM	SciSparc Secures Strategic Advantage with Grant of European Patent (GlobeNewswire) -11.43%
Apr-11-24 08:15AM	SciSparc to Acquire AutoMax (GlobeNewswire) +6.25%
Mar-27-24 09:12AM	Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression (GlobeNewswire) -6.45%
08:55AM	SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression (GlobeNewswire)
Mar-21-24 08:58AM	SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research (GlobeNewswire)
Mar-18-24 07:29AM	SciSparc Granted Another Patent, Strengthening its Core Technology in Canada (GlobeNewswire)
Mar-14-24 08:49AM	SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial (GlobeNewswire) -7.50%
Mar-12-24 08:14AM	SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structure (GlobeNewswire) -8.78%
Mar-08-24 07:11AM	SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder (GlobeNewswire) -6.11%
Mar-07-24 07:49AM	SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe (GlobeNewswire)
Mar-06-24 04:41PM	SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology (GlobeNewswire)
Feb-29-24 08:35AM	SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing (GlobeNewswire)
Feb-27-24 09:30AM	EXCLUSIVE: Psychedelic-Focused Firm Clearmind Medicine Submits Three New International Patent Applications For MDMA, Ibogaine And Ketamine Compounds (Benzinga)
07:58AM	SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds (GlobeNewswire)
07:58AM	Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds (GlobeNewswire)
Feb-20-24 07:14AM	SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds (GlobeNewswire) +15.52%
07:14AM	Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds (GlobeNewswire)
Jan-29-24 07:18AM	SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder (GlobeNewswire) -15.43%
Jan-24-24 01:49PM	Why Is SciSparc (SPRC) Stock Up 50% Today? (InvestorPlace) +78.03%
07:42AM	SciSparc Ltd. Announces $20 Million Standby Equity Purchase Agreement (GlobeNewswire)
Jan-19-24 09:28AM	SciSparc Advances the Acquisition Process of a Leading Vehicle Importer Company in Israel with the provision of a Bridge Loan of $1.4 million (GlobeNewswire) -8.77%
Jan-04-24 07:18AM	SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments (GlobeNewswire) -8.02%
07:18AM	Clearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based Treatments (GlobeNewswire)
Dec-13-23 02:02PM	Why Is SciSparc (SPRC) Stock Up 25% Today? (InvestorPlace) +39.51%
08:18AM	SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform (GlobeNewswire)
Dec-07-23 09:05AM	SciSparc Provides Updates Regarding the Non-Binding Letter of Intent to Acquire Leading Vehicle Importer Company in Israel (GlobeNewswire) -6.12%
Dec-05-23 08:47AM	Clearmind Medicine Achieved Positive Results in Cocaine Addiction Treatment (GlobeNewswire)
Dec-01-23 08:14AM	Weight Loss Treatment: SciSparc's Obesity Drug Showed Positive Results in a Pre-Clinical Trial (GlobeNewswire)
Nov-28-23 08:55AM	SciSparc Adopts Limited Duration Shareholder Rights Plan (GlobeNewswire) -9.22%
08:25AM	SciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment (GlobeNewswire)
Nov-27-23 08:41AM	SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform (GlobeNewswire)
Nov-24-23 08:55AM	New Hope for Children: SciSparc's patented CBD- Enhanced Solution for Autism Spectrum Disorder (GlobeNewswire) +35.22%
Nov-22-23 09:49AM	Why Is SciSparc (SPRC) Stock Up 20% Today? (InvestorPlace) +16.80%
07:42AM	SciSparc Signs Non-Binding Letter of Intent to Merge with Leading Vehicle Importer Company in Israel (GlobeNewswire)
Nov-15-23 10:55AM	Why Is SciSparc (SPRC) Stock Up 47% Today? (InvestorPlace) +48.17%
08:01AM	SciSparc Celebrates Major Breakthrough: Positive Results Show its Treatment has a Remarkable Impact on Alzheimer's Agitation (GlobeNewswire)
Nov-10-23 09:10AM	SciSparc Aims to Change Tourette Syndrome Treatments; Will Start a Phase IIb Trial with its Innovative Pharma-Grade THC-Based Medication (GlobeNewswire) -8.52%
Oct-31-23 11:08AM	Why Is SciSparc (SPRC) Stock Up 58% Today? (InvestorPlace) +64.81%
07:38AM	SciSparc Granted Patent from the Australian Patent Office for its Reduction of Opioids Use in Pain Management Technology (GlobeNewswire)
Oct-24-23 07:20AM	SciSparc Granted Patent for its Core Technology From the Australian Patent Office (GlobeNewswire) -13.72%
Oct-17-23 08:00AM	Why Is SciSparc (SPRC) Stock Up 105% Today? (InvestorPlace) +124.56%
Oct-16-23 09:45AM	Aegis Capital Corp. acted as Exclusive Placement Agent on a $5.0 Million Private Placement for SciSparc Ltd. (NASDAQ: SPRC) (ACCESSWIRE) -6.02%
08:17AM	SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification (GlobeNewswire)
Oct-13-23 04:28PM	SciSparc Ltd. Announces Closing of $5.026 Million Private Placement (GlobeNewswire) -9.67%
Oct-11-23 09:15AM	SciSparc Ltd. Announces Pricing of $5.026 Million Private Placement (GlobeNewswire) -12.94%
Oct-03-23 07:33AM	SciSparc Granted European Patent for its Core Technology (GlobeNewswire) +38.59%
Sep-29-23 07:45AM	SciSparc Initiated Its Clinical Trial with SCI-210 in Pediatrics with Autism Spectrum Disorder (GlobeNewswire) -7.16%
Sep-27-23 07:58AM	SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split (GlobeNewswire) +32.86%
Sep-20-23 06:30AM	SciSparc Announces 1-for-26 Reverse Share Split (GlobeNewswire) +14.14%
Sep-12-23 09:15AM	SciSparc Engages Investment Bank to Identify Potential Strategic Transaction Opportunities (GlobeNewswire) +6.38%
Sep-07-23 09:15AM	SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome (GlobeNewswire)
06:00AM	SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement (GlobeNewswire)
Aug-15-23 09:50AM	Aegis Capital Corp. acted as Sole Bookrunner on a $1.3 Million Underwritten Public Offering for SciSparc Ltd. (NASDAQ: SPRC) (ACCESSWIRE)
Aug-14-23 12:20PM	SciSparc Ltd. Closes $1.3 Million Underwritten Public Offering (GlobeNewswire)
Aug-10-23 09:10AM	SciSparc Ltd. Announces Pricing of $1.3 Million Underwritten Public Offering (GlobeNewswire) -62.83%
Aug-09-23 04:40PM	SciSparc Ltd. Announces Proposed Underwritten Public Offering of Approximately $1.3 Million (GlobeNewswire) +11.24%
Aug-01-23 10:30AM	EXCLUSIVE: Clearmind Medicine Files US Patent Application For Dyskinesia Treatment, Strengthening Its IP Portfolio (Benzinga)
09:00AM	SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S. (GlobeNewswire)
09:00AM	Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio (GlobeNewswire)
Jul-14-23 07:55AM	SciSparc to Commence Its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder (GlobeNewswire)
Jun-30-23 09:25AM	SciSparc Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany (GlobeNewswire) -6.95%
Jun-21-23 10:30AM	EXCLUSIVE: SciSparc's Tourette Syndrome Candidate Receives IRB Approval To Start Phase 2b Study In US (Benzinga)
09:00AM	SciSparc Announces IRB Approval to Conduct its Phase IIb Trial in Tourette Syndrome (GlobeNewswire)
Jun-16-23 09:05AM	SciSparc and Clearmind Medicine to Conduct a Study Evaluating Their Combination Treatment for Obesity and Metabolic Syndrome (GlobeNewswire) -5.27%
09:05AM	Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome (GlobeNewswire)
Jun-07-23 08:05AM	SciSparc Grants an Exclusive License for the Sales of CannAmide on the Amazon Marketplace in Canada to SciSparc Nutraceuticals (GlobeNewswire)
08:05AM	Jeffs' Brands: SciSparc Nutraceuticals was Granted an Exclusive License for the Sales of CannAmide on the Amazon Marketplace in Canada (GlobeNewswire)
Jun-02-23 09:00AM	SciSparc Announces Successful Final Phase IIa Results, Meeting End Points of its Phase IIa Alzheimer Disease Patients with Agitation Trial (GlobeNewswire) -24.95%

SciSparc Ltd. is a clinical stage pharmaceutical company, which focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The firm initiated two internal drug development programs based on repurposing an FDA approved synthetic cannabinoid (dronabinol): Joint Pharma developing THX-TS01 targeted to the treatment of TS and Brain Bright Pharma developing THX-ULD01 targeted to the high value and under-served market of MCIs. Its products include SCI-110, SCI-210, SCI-160, and CannAmide. The company was founded on August 23, 2004 and is headquartered in Tel Aviv, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SPRC

SciSparc Ltd

Upgrade your FINVIZ experience